Immunobiology and pathogenesis of hepatitis B virus infection

M Iannacone, LG Guidotti - Nature Reviews Immunology, 2022 - nature.com
Hepatitis B virus (HBV) is a non-cytopathic, hepatotropic virus with the potential to cause a
persistent infection, ultimately leading to cirrhosis and hepatocellular carcinoma. Over the …

How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?

GLH Wong, E Gane, ASF Lok - Journal of hepatology, 2022 - Elsevier
Functional cure of hepatitis B is defined as sustained undetectable circulating HBsAg and
HBV DNA after a finite course of treatment. Barriers to HBV cure include the reservoirs for …

Longitudinal liver sampling in patients with chronic hepatitis B starting antiviral therapy reveals hepatotoxic CD8+ T cells

S Nkongolo, D Mahamed, A Kuipery… - The Journal of …, 2023 - Am Soc Clin Investig
Accumulation of activated immune cells results in nonspecific hepatocyte killing in chronic
hepatitis B (CHB), leading to fibrosis and cirrhosis. This study aims to understand the …

The scientific basis of combination therapy for chronic hepatitis B functional cure

SG Lim, TF Baumert, C Boni, E Gane… - Nature Reviews …, 2023 - nature.com
Functional cure of chronic hepatitis B (CHB)—or hepatitis B surface antigen (HBsAg) loss
after 24 weeks off therapy—is now the goal of treatment, but is rarely achieved with current …

Getting to HBV cure: The promising paths forward

S Fung, HSJ Choi, A Gehring, HLA Janssen - Hepatology, 2022 - Wiley Online Library
Chronic HBV infection is a global public health burden estimated to impact nearly 300
million persons worldwide. Despite the advent of potent antiviral agents that effectively …

Effects of hepatitis B surface antigen on virus-specific and global T cells in patients with chronic hepatitis B virus infection

N Le Bert, US Gill, M Hong, K Kunasegaran, DZM Tan… - Gastroenterology, 2020 - Elsevier
Background & Aims Chronic hepatitis B virus (HBV) infection is characterized by the
presence of defective viral envelope proteins (hepatitis B surface antigen [HBsAg]) and the …

Targeting innate and adaptive immune responses to cure chronic HBV infection

AJ Gehring, U Protzer - Gastroenterology, 2019 - Elsevier
Fewer than 1% of chronic hepatitis B virus infections per year are cured with antiviral
treatment. This creates a need for long-term treatment, which poses challenges for patients …

Restoration of HBV-specific CD8+ T-cell responses by sequential low-dose IL-2 treatment in non-responder patients after IFN-α therapy

D Wang, B Fu, X Shen, C Guo, Y Liu, J Zhang… - … and Targeted Therapy, 2021 - nature.com
Patients with chronic hepatitis B (CHB) undergoing interferon (IFN)-α-based therapies often
exhibit a poor HBeAg serological response. Thus, there is an unmet need for new therapies …

Phenotypic and functional differences of HBV core-specific versus HBV polymerase-specific CD8+ T cells in chronically HBV-infected patients with low viral load

A Schuch, ES Alizei, K Heim, D Wieland, MM Kiraithe… - Gut, 2019 - gut.bmj.com
Objective A hallmark of chronic HBV (cHBV) infection is the presence of impaired HBV-
specific CD8+ T cell responses. Functional T cell exhaustion induced by persistent antigen …

Attenuated effector T cells are linked to control of chronic HBV infection

K Heim, Sagar, Ö Sogukpinar, S Llewellyn-Lacey… - Nature …, 2024 - nature.com
Hepatitis B virus (HBV)-specific CD8+ T cells play a dominant role during acute-resolving
HBV infection but are functionally impaired during chronic HBV infection in humans. These …